Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04765709
Title Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC (BRIDGE)
Acronym BRIDGE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mario Negri Institute for Pharmacological Research
Indications
Therapies
Age Groups: adult | senior
Covered Countries ITA | FRA | ESP


No variant requirements are available.